Zydus Lifesciences Limited — Trastuzumab Exporter Profile
Indian Pharmaceutical Exporter · #3 for Trastuzumab · $3.4M export value · DGFT Verified
Zydus Lifesciences Limited is the #3 Indian exporter of Trastuzumab with $3.4M in export value and 68 verified shipments. Zydus Lifesciences Limited holds a 4.4% market share in Trastuzumab exports across 8 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.
Zydus Lifesciences Limited — Trastuzumab Export Profile: Buyers & Destinations
Where Does Zydus Lifesciences Limited Export Trastuzumab?
| Country | Value | Shipments | Share |
|---|---|---|---|
| KENYA | $210.2K | 5 | 18.2% |
| CAMBODIA | $186.0K | 4 | 16.1% |
| BOLIVIA | $174.3K | 6 | 15.1% |
| INDONESIA | $150.0K | 3 | 13.0% |
| MEXICO | $150.0K | 3 | 13.0% |
| NEPAL | $134.5K | 44 | 11.7% |
| MYANMAR | $100.0K | 2 | 8.7% |
| MAURITIUS | $48.5K | 1 | 4.2% |
Zydus Lifesciences Limited exports Trastuzumab to 8 countries. The largest destination is KENYA accounting for 18.2% of Zydus Lifesciences Limited's Trastuzumab shipments, followed by CAMBODIA (16.1%) and BOLIVIA (15.1%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Trastuzumab from Zydus Lifesciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ZYDUS PHARMACEUTICALS M?XICO S.A. D | MEXICO | $150.0K | 3 |
| FARMEDICAL S.R.L. | BOLIVIA | $147.5K | 5 |
| MEGA LIFESCIENCES PTY LTD | CAMBODIA | $140.2K | 3 |
| RIPPLE PHARMACEUTICALS | KENYA | $110.2K | 3 |
| RIPPLE PHARMACEUTICALS LTD | KENYA | $100.0K | 2 |
| KIMIA FARMA TBK, PT | INDONESIA | $100.0K | 2 |
| D. K. M. PHARMACEUTICALS PVT. LTD. | NEPAL | $96.4K | 29 |
| KIMIA FARMA TBK. PT | INDONESIA | $50.0K | 1 |
| MYIT MAHAR TRADING CO LIMITED | MYANMAR | $50.0K | 1 |
| MYIT MAHAR TRADING CO.LIMITED | MYANMAR | $50.0K | 1 |
Zydus Lifesciences Limited supplies Trastuzumab to 15 buyers globally. The largest buyer is ZYDUS PHARMACEUTICALS M?XICO S.A. D (MEXICO), followed by FARMEDICAL S.R.L. (BOLIVIA) and MEGA LIFESCIENCES PTY LTD (CAMBODIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Trastuzumab Export Value and How Much Does Zydus Lifesciences Limited Contribute?
India exported $37.2M worth of Trastuzumab through 1,882 shipments from 179 suppliers to 108 countries, serving 329 buyers globally. Zydus Lifesciences Limited contributes $3.4M to this total, accounting for 4.4% of India's Trastuzumab exports. Zydus Lifesciences Limited ships Trastuzumab to 8 countries through 15 buyers.
What Is the Average Shipment Value for Zydus Lifesciences Limited's Trastuzumab Exports?
Zydus Lifesciences Limited's average Trastuzumab shipment value is $50.0K per consignment, based on 68 shipments totaling $3.4M. The largest destination is KENYA (18.2% of Zydus Lifesciences Limited's Trastuzumab exports).
How Does Zydus Lifesciences Limited Compare to Other Indian Trastuzumab Exporters?
Zydus Lifesciences Limited ranks #3 among 179 Indian Trastuzumab exporters with a 4.4% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($25.1M), RELIANCE LIFE SCIENCES PRIVATE LIMITED ($3.8M), ZYDUS LIFESCIENCES LIMITED ($3.4M). Zydus Lifesciences Limited processed 68 shipments to 8 destination countries.
What Trastuzumab Formulations Does Zydus Lifesciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| Mamitra(Trastu Inj440mg)withDil.VialSLMX(TRASTUZUMAB LYOPHILIZED POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION) | $150.0K | 3 |
| VIVITRA (TRASTUZUMAB 440MG) (TRASTUZUMAB | $142.5K | 3 |
| TRASTUZUMAB 440MG INJ 1 VIAL (TRASTUZUMA | $97.3K | 3 |
| VIVITRA 440MG INJECTION 1 VIAL (TRASTUZUMAB 440MG) (1002X1X1VIAL)VLS | $50.0K | 1 |
| VIVITRA 440 MG INJECTION 1 VIAL (TRASTUZUMAB)(1X1 VIAL)VLS | $50.0K | 1 |
| VIVITRA 440 MG INJECTION 1 VIAL (TRASTUZUMAB) QTY. 457.000-AS PER INVOICENOS | $50.0K | 1 |
| VIVITRA (TRASTUZUMAB 440MG)(TRASTUZUMAB(1X1 VIAL) | $50.0K | 1 |
| VIVITRA 440MG INJECTION 1 VIAL (TRASTUZUMAB 440MG) (500X1X1VIAL) | $50.0K | 1 |
| VIVITRA 440MG INJECTION 1 VIAL (TRASTUZUMAB 440MG) (1000X1X1VIAL) | $50.0K | 1 |
| VIVITRA 440MG INJECTION 1 VIAL (TRASTUZUMAB) (273X1X1VIAL) | $50.0K | 1 |
Zydus Lifesciences Limited exports 47 distinct Trastuzumab formulations including tablets, capsules, syrups, and combination drugs. The top formulation is Mamitra(Trastu Inj440mg)withDil.VialSLMX(TRASTUZUMAB LYOPHIL with 3 shipments worth $150.0K.
How Does Zydus Lifesciences Limited Compare to Nearest Trastuzumab Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED | $25.1M | 503 | 7 | $50.0K |
| 4 | RELIANCE LIFE SCIENCES PRIVATE LIMITED | $3.8M | 75 | 15 | $50.0K |
| 3 | ZYDUS LIFESCIENCES LIMITED ★ | $3.4M | 68 | 8 | $50.0K |
| 2 | BIOCON BIOLOGICS INDIA LIMITED | $1.9M | 39 | 17 | $50.0K |
| 9 | NU HOSPITALS PRIVATE LIMITED | $673.7K | 62 | 1 | $10.9K |
Zydus Lifesciences Limited ranks #3 among 179 Indian Trastuzumab exporters. Average shipment value of $50.0K compared to the market average of $208.0K. The closest competitors by value are MYLAN LABORATORIES LIMITED and RELIANCE LIFE SCIENCES PRIVATE LIMITED.
Which Indian Ports Ship Trastuzumab Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 379 | 20.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 319 | 17.0% |
| BANGALORE AIR | 254 | 13.5% |
| BANGALORE ACC (INBLR4) | 186 | 9.9% |
| Bombay Air | 99 | 5.3% |
| DELHI AIR | 74 | 3.9% |
| AHEMDABAD AIR ACC (INAMD4) | 62 | 3.3% |
| Bangalore Air | 58 | 3.1% |
Geopolitical & Trade Policy Impact on Zydus Lifesciences Limited's Trastuzumab Exports
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Zydus Lifesciences Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Trastuzumab, top products include Losartan, Carvedilol, Iron, Mesalamine, Omeprazole. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Trastuzumab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Trastuzumab shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Zydus Lifesciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 68 individual customs records matching Zydus Lifesciences Limited exporting Trastuzumab, covering 47 formulations to 8 countries via 15 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 108+ countries, 329+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Trastuzumab Export Data from Zydus Lifesciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Trastuzumab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile →
81 products · $346.3M total trade · 25 categories
Trastuzumab Stats
Company Overview
Top Products by Zydus Lifesciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Trastuzumab. For current shipment-level data, contact TransData Nexus.